Guyasuta Investment Advisors Boosted By $812,208 Its Oracle (ORCL) Holding; Profile of 8 Analysts Covering Merit Medical Systems, Inc. (MMSI)

January 17, 2018 - By Richard Conner

Guyasuta Investment Advisors Inc increased Oracle Corp (ORCL) stake by 6.13% reported in 2017Q3 SEC filing. Guyasuta Investment Advisors Inc acquired 16,921 shares as Oracle Corp (ORCL)’s stock rose 5.35%. The Guyasuta Investment Advisors Inc holds 293,127 shares with $14.17 million value, up from 276,206 last quarter. Oracle Corp now has $207.15 billion valuation. The stock increased 0.91% or $0.45 during the last trading session, reaching $50.04. About 8.37M shares traded. Oracle Corporation (NYSE:ORCL) has risen 14.08% since January 17, 2017 and is uptrending. It has underperformed by 2.62% the S&P500.

Among 8 analysts covering Merit Medical (NASDAQ:MMSI), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Merit Medical had 18 analyst reports since October 23, 2015 according to SRatingsIntel. Bank of America initiated the shares of MMSI in report on Thursday, July 20 with “Buy” rating. The firm has “Buy” rating by Craig Hallum given on Thursday, July 27. The stock has “Buy” rating by Canaccord Genuity on Tuesday, January 2. The stock of Merit Medical Systems, Inc. (NASDAQ:MMSI) earned “Outperform” rating by Raymond James on Monday, August 28. The rating was maintained by Canaccord Genuity with “Buy” on Thursday, July 27. Canaccord Genuity maintained Merit Medical Systems, Inc. (NASDAQ:MMSI) rating on Sunday, October 8. Canaccord Genuity has “Buy” rating and $45.0 target. On Friday, October 23 the stock rating was downgraded by Barrington Research to “Mkt Perform”. The rating was upgraded by Barrington Research on Monday, October 26 to “Outperform”. The stock of Merit Medical Systems, Inc. (NASDAQ:MMSI) earned “Buy” rating by SunTrust on Thursday, November 16. On Monday, September 4 the stock rating was maintained by Canaccord Genuity with “Buy”. See Merit Medical Systems, Inc. (NASDAQ:MMSI) latest ratings:

02/01/2018 Broker: Canaccord Genuity Rating: Buy New Target: $50.0 Maintain
30/11/2017 Broker: Wells Fargo Rating: Buy New Target: $51.0 Maintain
16/11/2017 Broker: SunTrust Rating: Buy New Target: $47.0 Maintain
16/11/2017 Broker: Canaccord Genuity Rating: Buy New Target: $47.5 Maintain
26/10/2017 Broker: Canaccord Genuity Rating: Buy Old Target: $45 New Target: $47.5 Maintain
08/10/2017 Broker: Canaccord Genuity Rating: Buy New Target: $45.0 Maintain
04/09/2017 Broker: Canaccord Genuity Rating: Buy New Target: $45.0 Maintain
28/08/2017 Broker: Raymond James Old Rating: Strong Buy New Rating: Outperform Downgrade
27/07/2017 Broker: Craig Hallum Rating: Buy New Target: $50.0000 Maintain
27/07/2017 Broker: Canaccord Genuity Rating: Buy New Target: $45.0000 Maintain

Guyasuta Investment Advisors Inc decreased Conagra Brands Inc (NYSE:CAG) stake by 13,890 shares to 7,050 valued at $238,000 in 2017Q3. It also reduced Packaging Corp Amer (NYSE:PKG) stake by 5,785 shares and now owns 183,495 shares. Aerojet Rocketdyne Hldgs Inc was reduced too.

Among 38 analysts covering Oracle (NYSE:ORCL), 28 have Buy rating, 0 Sell and 10 Hold. Therefore 74% are positive. Oracle had 103 analyst reports since July 30, 2015 according to SRatingsIntel. The stock of Oracle Corporation (NYSE:ORCL) has “Buy” rating given on Friday, August 25 by RBC Capital Markets. The firm earned “Buy” rating on Wednesday, March 16 by Canaccord Genuity. The stock of Oracle Corporation (NYSE:ORCL) has “Buy” rating given on Monday, July 24 by Stifel Nicolaus. BMO Capital Markets maintained the stock with “Outperform” rating in Friday, September 16 report. The rating was maintained by Jefferies with “Buy” on Friday, September 15. The stock of Oracle Corporation (NYSE:ORCL) has “Buy” rating given on Friday, August 25 by Jefferies. The firm has “Outperform” rating by RBC Capital Markets given on Friday, December 16. UBS maintained the stock with “Buy” rating in Wednesday, March 16 report. RBC Capital Markets maintained Oracle Corporation (NYSE:ORCL) rating on Thursday, June 22. RBC Capital Markets has “Outperform” rating and $53 target. Jefferies upgraded the shares of ORCL in report on Thursday, July 30 to “Buy” rating.

Investors sentiment increased to 1.13 in 2017 Q3. Its up 0.18, from 0.95 in 2017Q2. It increased, as 67 investors sold ORCL shares while 498 reduced holdings. 122 funds opened positions while 519 raised stakes. 2.32 billion shares or 1.54% less from 2.35 billion shares in 2017Q2 were reported. Allsquare Wealth Mgmt Ltd holds 0.05% of its portfolio in Oracle Corporation (NYSE:ORCL) for 1,300 shares. Burgundy Asset Management has 6.11M shares. Adage Capital Gru Ltd Com reported 3.99M shares. Catawba Capital Va holds 102,086 shares or 1.12% of its portfolio. East Coast Asset Ltd Liability Corporation stated it has 0.05% of its portfolio in Oracle Corporation (NYSE:ORCL). Woodley Farra Manion Management owns 12,555 shares for 0.07% of their portfolio. Moreover, Thomaspartners Inc has 1.78% invested in Oracle Corporation (NYSE:ORCL). Bremer Trust National Association holds 0.11% or 8,162 shares in its portfolio. Intact Investment Mgmt has invested 0.08% of its portfolio in Oracle Corporation (NYSE:ORCL). Boston Family Office Ltd Liability Corporation owns 252,496 shares for 1.39% of their portfolio. Ls Invest reported 253,401 shares or 0.73% of all its holdings. Coldstream Capital Mgmt Incorporated invested 0.08% in Oracle Corporation (NYSE:ORCL). Barometer Capital Mngmt invested 1.47% in Oracle Corporation (NYSE:ORCL). Forte Limited Liability Co Adv owns 7,925 shares or 0.12% of their US portfolio. Lombard Odier Asset Management (Switzerland), a Switzerland-based fund reported 12,891 shares.

Investors sentiment decreased to 1.28 in 2017 Q3. Its down 0.21, from 1.49 in 2017Q2. It dived, as 14 investors sold Merit Medical Systems, Inc. shares while 71 reduced holdings. 44 funds opened positions while 65 raised stakes. 44.33 million shares or 0.69% more from 44.02 million shares in 2017Q2 were reported. Balyasny Asset Mgmt Limited Liability Co reported 0% in Merit Medical Systems, Inc. (NASDAQ:MMSI). 373,458 were reported by National Bank & Trust Of America De. Employees Retirement System Of Texas reported 0.01% of its portfolio in Merit Medical Systems, Inc. (NASDAQ:MMSI). Arrowstreet Ltd Partnership owns 396,374 shares for 0.04% of their portfolio. Hancock Hldg owns 0.05% invested in Merit Medical Systems, Inc. (NASDAQ:MMSI) for 29,500 shares. Atria Ltd invested in 0.02% or 7,531 shares. Amp Capital Invsts accumulated 0% or 9,800 shares. 374,091 were reported by Pub Employees Retirement Association Of Colorado. Wells Fargo And Company Mn reported 0% in Merit Medical Systems, Inc. (NASDAQ:MMSI). Aristotle Boston Llc has invested 1.77% of its portfolio in Merit Medical Systems, Inc. (NASDAQ:MMSI). Glenmede Na holds 0.1% of its portfolio in Merit Medical Systems, Inc. (NASDAQ:MMSI) for 541,426 shares. State Of Alaska Department Of Revenue, a Alaska-based fund reported 9,897 shares. The Australia-based Macquarie Gru Ltd has invested 0.08% in Merit Medical Systems, Inc. (NASDAQ:MMSI). Symphony Asset Limited Liability Corporation has 16,167 shares. 45,267 were accumulated by D E Shaw & Inc.

Since August 3, 2017, it had 0 buys, and 6 sales for $1.99 million activity. STANGER KENT W also sold $407,782 worth of Merit Medical Systems, Inc. (NASDAQ:MMSI) shares. ANDERSON A SCOTT sold $1.03M worth of stock or 25,000 shares. On Thursday, August 3 the insider Millner F. Ann sold $127,389.

Merit Medical Systems, Inc. designs, develops, makes, and markets medical products for interventional and diagnostic procedures worldwide. The company has market cap of $2.34 billion. The companyÂ’s Cardiovascular segment offers cardiology and radiology devices for diagnosing and treating coronary arterial, peripheral vascular, and other non-vascular diseases; and embolotherapeutic products. It has a 79.56 P/E ratio. It also provides vascular access products; guide wires, inflation devices, and diagnostic catheters for use in angiography procedures; therapeutic infusion systems and safety products; drainage catheters and drainage access products, support catheters, vascular retrieval devices, and dialysis access products; and embosphere microspheres and delivery systems, and microcatheters.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts